Printer Friendly

India : Zydus receives final approval from the USFDA for Clindamycin Phosphate and Benzoyl Peroxide Gel.

Zydus Cadila has received the final approval from the USFDA to market Clindamycin Phosphate and Benzoyl Peroxide Gel, (US RLD -DUAC Gel), 1.2%/5%. It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

This combination medication is used to treat a certain type of acne (inflammatory acne vulgaris). It helps to decrease the number of acne pimples. Clindamycin is an antibiotic that stops the growth of acne-causing bacteria. Benzoyl peroxide can also stop the growth of bacteria as well as reduce oil production in the skin.

The group now has 242 approvals and has so far filed over 340 ANDAs since the commencement of the filing process in FY 2003-04.

[c] 2019 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2019 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Geographic Code:9INDI
Date:Jan 5, 2019
Words:127
Previous Article:United Kingdom : Northern Trust 2019 Outlook Sees No Recession in Developed Markets and Global Growth Continuing.
Next Article:United Kingdom : US Tech Sector Hiring Cooled Off in December, Comptia Analysis Shows.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters